Norges Bank’s Relmada Therapeutics RLMD Stock Holding History

Norges Bank’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-54,900	Closed	-$2.03M	–	2169
2022 Q3	$2.03M	Sell	54,900 -1,800	-3%	-$49.9K	﹤0.01%	1912
2022 Q2	$1.08M	Buy	+56,700	New	+$1.24M	﹤0.01%	1957
2022 Q1	–	Sell	-98,500	Closed	-$2.22M	–	2222
2021 Q4	$2.22M	Hold	98,500	–	–	﹤0.01%	2022
2021 Q3	$2.58M	Buy	+98,500	New	+$2.64M	﹤0.01%	2011

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank's RLMD Position: Q4 2022 in Review

Norges Bank sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 54,900 shares — an estimated $2.03M sold.

Norges Bank first reported a position in RLMD in Q3 2021 and held it in 4 quarters. The position peaked at $2.58M in Q3 2021. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Norges Bank reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Norges Bank sold 54,900 Relmada Therapeutics shares in Q4 2022, an estimated $2.03M.
Norges Bank first reported a position in Relmada Therapeutics in Q3 2021 and held it in 4 quarters.
Norges Bank's Relmada Therapeutics position peaked at $2.58M in Q3 2021.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Norges Bank's 13F filing for Q4 2022, filed 14 Feb 2023.